CRISPR/Cas9 is a novel prize-winning gene-editing technology that revolutionized personalized medicine. This technology allows precise, rapid, and long-lasting cure of genetic disorders that otherwise does have no cure.
The recent results from human clinical trials on eye disorders and blood cell disorders have shown that the CRISPR-based technology is safe, and has shown durable effects. With his promising technology three companies are pioneering CRISPR-based treatments.
CRISPR Therapeutics (Nasdaq: CRSP)
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Editas Medicine (Nasdaq: EDIT)
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
The company has a promising pipeline with clinical development programs for the treatment of eye disorders and sickle cell disease.
Intellia Therapeutics (Nasdaq: NTLA)
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases.